Free Trial

Radiopharm Theranostics (RADX) Competitors

Radiopharm Theranostics logo
$5.33 -0.23 (-4.14%)
As of 10/24/2025 03:59 PM Eastern

RADX vs. EPRX, GNFT, SGMO, BHST, CHRS, GNLX, MXCT, IPHA, PRE, and NKTX

Should you be buying Radiopharm Theranostics stock or one of its competitors? The main competitors of Radiopharm Theranostics include Eupraxia Pharmaceuticals (EPRX), GENFIT (GNFT), Sangamo Therapeutics (SGMO), BioHarvest Sciences (BHST), Coherus Oncology (CHRS), Genelux (GNLX), MaxCyte (MXCT), Innate Pharma (IPHA), Prenetics Global (PRE), and Nkarta (NKTX). These companies are all part of the "med - biomed/gene" industry.

Radiopharm Theranostics vs. Its Competitors

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

Radiopharm Theranostics has higher revenue and earnings than Eupraxia Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.85-6.44
Radiopharm Theranostics$2.35M17.87-$24.83MN/AN/A

Eupraxia Pharmaceuticals presently has a consensus price target of $11.00, indicating a potential upside of 101.10%. Radiopharm Theranostics has a consensus price target of $15.00, indicating a potential upside of 181.43%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts clearly believe Radiopharm Theranostics is more favorable than Eupraxia Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eupraxia Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Radiopharm Theranostics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, Eupraxia Pharmaceuticals had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Eupraxia Pharmaceuticals and 1 mentions for Radiopharm Theranostics. Eupraxia Pharmaceuticals' average media sentiment score of 1.93 beat Radiopharm Theranostics' score of 1.89 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Eupraxia Pharmaceuticals Very Positive
Radiopharm Theranostics Very Positive

Radiopharm Theranostics' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eupraxia PharmaceuticalsN/A -626.84% -118.31%
Radiopharm Theranostics N/A N/A N/A

Summary

Radiopharm Theranostics beats Eupraxia Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Get Radiopharm Theranostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RADX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RADX vs. The Competition

MetricRadiopharm TheranosticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$43.83M$3.43B$6.23B$10.66B
Dividend YieldN/A2.27%5.71%4.82%
P/E RatioN/A24.2730.2930.24
Price / Sales17.87494.27591.44133.15
Price / CashN/A45.5737.0161.44
Price / Book1.5110.4012.046.60
Net Income-$24.83M-$52.62M$3.32B$276.82M
7 Day Performance-25.04%2.09%1.89%2.58%
1 Month Performance-7.30%12.32%7.68%3.76%
1 Year PerformanceN/A14.12%56.01%33.84%

Radiopharm Theranostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RADX
Radiopharm Theranostics
3.3694 of 5 stars
$5.33
-4.1%
$15.00
+181.4%
N/A$43.83M$2.35M0.00N/APositive News
EPRX
Eupraxia Pharmaceuticals
2.8871 of 5 stars
$5.87
-0.7%
$11.00
+87.4%
+119.7%$212.53MN/A-6.9129Short Interest ↑
GNFT
GENFIT
2.2327 of 5 stars
$4.16
-1.9%
$7.00
+68.3%
-23.3%$211.92M$76.77M0.00120Gap Down
SGMO
Sangamo Therapeutics
2.2648 of 5 stars
$0.64
-6.5%
$4.50
+597.8%
-57.5%$208.18M$57.80M-2.22480Positive News
BHST
BioHarvest Sciences
2.5513 of 5 stars
$11.50
-9.1%
$13.67
+18.8%
N/A$207.70M$25.19M-16.43N/ANews Coverage
Analyst Forecast
Short Interest ↑
Gap Up
CHRS
Coherus Oncology
4.2051 of 5 stars
$1.71
-3.9%
$4.51
+163.9%
+107.8%$206.88M$266.96M1.10330News Coverage
Analyst Forecast
GNLX
Genelux
1.3839 of 5 stars
$5.36
-1.5%
$20.33
+279.4%
+210.3%$205.49M$10K-6.2310Analyst Forecast
Gap Up
MXCT
MaxCyte
3.9685 of 5 stars
$1.77
-3.3%
$7.00
+295.5%
-57.1%$195.09M$38.63M-4.1280
IPHA
Innate Pharma
2.8197 of 5 stars
$2.14
+1.4%
$6.50
+203.7%
+19.0%$194.51M$21.77M0.00220
PRE
Prenetics Global
1.1524 of 5 stars
$15.86
+6.9%
$9.00
-43.3%
+255.8%$192.70M$30.62M-3.971Positive News
NKTX
Nkarta
2.7185 of 5 stars
$2.49
-5.3%
$13.50
+442.2%
-33.8%$186.79MN/A-1.68140News Coverage
Positive News
Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:RADX) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners